This phase I/II trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in patients with gastrointestinal cancer receiving fluoropyrimidine therapy. Some patients develop chest pain (possibly even a heart attack, a drop in heart function, or a rhythm abnormality) during treatment with a class of cancer drugs known as fluoropyrimidines, which include 5-Fluorouracil (5-FU) and capecitabine. These side effects are believed to be due to the development of an abnormal reactivity of the blood vessels referred to as vasospasm. Vasotoxicity is damage or toxicity inflicted upon blood vessels (vascular system), often causing dysfunction, remodeling, or narrowing (vasoconstriction). It is a broad term used to describe the detrimental effects of certain agents, such as chemotherapy drugs. Researchers want to evaluate how often the reactivity of blood vessels becomes abnormal, during the treatment with 5-FU or capecitabine and how clinically relevant and controllable/preventable this phenomenon is in patients with gastrointestinal cancer.

Start Date31 Mar 2026

Sponsor / Collaborator

Mayo Clinic

CTR20254016

/ CompletedNot Applicable

随机、开放、单剂量、两制剂、双交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服单硝酸异山梨酯片后的生物等效性正式试验

[Translation] A randomized, open-label, single-dose, two-formulation, double-crossover controlled trial was conducted to evaluate the bioequivalence of a single oral dose of isosorbide mononitrate tablets in healthy Chinese subjects in the fasting and fed states.

主要目的：观察健康受试者空腹及餐后状态下单剂量口服受试制剂单硝酸异山梨酯片（规格：20mg，生产厂家：山东博瀚制药有限公司）后血药浓度的经时过程，估算相应的药代动力学参数；并以单硝酸异山梨酯片（商品名：Monoket®，规格：20mg，持证商：Merus Labs Luxco II, S.à.r.l.）为参比制剂，进行人体生物等效性正式试验，为该药注册申报和临床应用提供参考依据。次要目的：观察受试者空腹及餐后状态下口服受试制剂和参比制剂的安全性。

[Translation]

The primary objective was to observe the time course of plasma drug concentrations of the test formulation, isosorbide mononitrate tablets (20 mg, manufacturer: Shandong Bohan Pharmaceutical Co., Ltd.), in healthy volunteers after a single oral dose in the fasting and fed states, and to estimate the corresponding pharmacokinetic parameters. A formal bioequivalence study was conducted in humans using isosorbide mononitrate tablets (Monoket®, 20 mg, licensee: Merus Labs Luxco II, S.à.r.l.) as the reference formulation, to provide a reference for drug registration and clinical application. The secondary objective was to observe the safety of the test and reference formulations after oral administration in the fasting and fed states.

Start Date17 Dec 2025

Sponsor / Collaborator

Shandong Bohan Pharmaceutical Co., Ltd.

CTR20254354

/ CompletedNot Applicable

随机、开放、两制剂、交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次单次口服受试制剂单硝酸异山梨酯缓释片后的生物等效性正式试验

[Translation] A randomized, open-label, two-dose, crossover controlled trial was conducted to evaluate the bioequivalence of a single oral dose of isosorbide mononitrate extended-release tablets in healthy Chinese subjects under fasting and postprandial conditions.

主要目的：以山东博瀚制药有限公司提供的单硝酸异山梨酯缓释片为受试制剂；并以Kern Pharma S.L.持证的单硝酸异山梨酯缓释片为参比制剂，进行人体相对生物利用度和生物等效性评价。

[Translation]

Main objective: To evaluate the relative bioavailability and bioequivalence of isosorbide mononitrate sustained-release tablets provided by Shandong Bohan Pharmaceutical Co., Ltd., as the test formulation, and isosorbide mononitrate sustained-release tablets certified by Kern Pharma S.L., as the reference formulation.

Start Date05 Dec 2025

Sponsor / Collaborator

Shandong Bohan Pharmaceutical Co., Ltd.

100 Clinical Results associated with Isosorbide Mononitrate

100 Translational Medicine associated with Isosorbide Mononitrate

100 Patents (Medical) associated with Isosorbide Mononitrate

1,699

Literatures (Medical) associated with Isosorbide Mononitrate

31 Dec 2026·PHARMACEUTICAL BIOLOGY

Comparative cardioprotective effects of Kuanxiong Aerosol and its individual components in a rat model of acute myocardial infarction

Article

Author: Yang, Tao ; Peng, Xiao-kang ; Xu, Meng-meng ; Fan, Xiao-jing ; Tang, Yu ; Zheng, Yuan-hang ; Luo, Yi ; Zhang, Jin-ting ; Zhu, Yang-yang ; Chen, Ye-feng ; Qian, Kai

CONTEXT:

Kuanxiong Aerosol (KXA), composed of volatile oils from sandalwood (Santalum album L.), galangal (Alpiniae Officinarum Rhizoma), asarum (Asari Radix), pepper (Piper longum L.), and borneol, is used to treat cardiovascular conditions. However, its scientific basis and the contribution of its individual components remain poorly understood.

OBJECTIVE:

We investigated the chemical composition, dose-dependent efficacy, and cardioprotective effects of KXA and its individual components in a rat acute myocardial infarction (AMI) model.

MATERIALS AND METHODS:

KXA and its components were characterized using GC-MS. AMI was induced in rats by left anterior descending (LAD) ligation. Animals were pretreated with low-dose (120 µL/kg) or high-dose (200 µL/kg) KXA, its individual components (120 µL/kg), or isosorbide mononitrate (ISMN; 5 mg/kg). Cardioprotective effects were assessed via electrocardiography, TTC staining, histopathology, hemodynamics, and serum cardiac biomarkers.

RESULTS:

Low-dose KXA provided significant cardioprotection, improving ST-segment elevation, infarct size, histopathology, hemodynamic, and biochemical markers, with efficacy comparable or more pronounced to ISMN. In contrast, high-dose KXA was less effective. Sandalwood and asarum oils were the primary anti-ischemic agents, while galangal oil, pepper oil, and borneol provided complementary anti-fibrotic and hemodynamic support. However, individual components or high doses exhibited limited efficacy and potential adverse effects.

DISCUSSION AND CONCLUSIONS:

KXA's cardioprotection stems from the synergistic action of its components targeting ischemia, fibrosis, inflammation, and cardiac dysfunction. This study provides evidence supporting the cardioprotective potential of low-dose, multi-component KXA, indicating that such balanced formulations may offer broader benefits than high-dose or single-agent approaches. Further research is needed to elucidate the molecular mechanisms and refine the formulation for clinical translation.

01 Feb 2026·Alzheimers & Dementia

Patient and public involvement and engagement in clinical trials at scale: Analysis of the first 3250 responses on the POrtal for Patient and Public Engagement in Dementia (POPPED)

Article

Author: Carpenter, James ; Reeves, Suzanne ; Whittle, Joanne ; Ali, Shabinah ; Pointon, Linda ; Qin, Hongyi ; Dunne, Ross ; Rizzo, Laura ; Raymont, Vanessa ; Iqbal, Sabahat ; Bonet‐Olivares, Cristina ; Malhotra, Paresh ; Underwood, Benjamin R

Abstract:

INTRODUCTION:

Patient and public involvement and engagement (PPIE) improves research quality but is often limited in scale. This study explored the potential for large‐scale PPIE using a Web‐based approach.

METHODS:

We created an online portal to gather public views on dementia research and a UK‐based adaptive platform trial testing repurposed Alzheimer's disease drugs. Participants ranked four anonymized drugs and completed discrete choice experiments on treatment trade‐offs. Analyses were stratified by sex, age, and dementia experience.

RESULTS:

Among 3250 people across 27 countries (87.4% UK‐based), 79.6% expressed positive attitudes toward the trial. Metformin was the most preferred drug, followed by atomoxetine, isosorbide mononitrate, and levetiracetam. Probability of severe side effects was the most influential treatment attribute, followed by probability of mild side effects and type of evidence. Subgroup analyses supported the main findings.

DISCUSSION:

Web‐based PPIE can effectively inform dementia research at scale and provides a reusable resource for other studies.

31 Dec 2025·Journal of Maternal-Fetal & Neonatal Medicine

Statement of Retraction: Comparing vaginal misoprostol versus Foley catheter plus vaginal isosorbide mononitrate for labor induction

Article

News (Medical) associated with Isosorbide Mononitrate

14 Aug 2025

·www.prnewswire.com

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

OSLO, Norway, Aug. 14, 2025 /PRNewswire/ -- In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down from NOK 277.2 million in 2024. Excluding the milestone license fee from Orion corporation of NOK 22.7 million in 2024, revenues grew by 5.8 per cent YoY, gross margin improved to 37.3 per cent, compared to 37.0 per cent in Q2 2024 and EBITDA amounted to NOK 22.9 million compared to EBITDA of NOK 18.4 million in 2024. The performance was primarily driven by the Hospital area, particularly the antibiotics portfolio. Recent tender wins have driven sales growth for the antibiotics portfolio, which is up 48.4% YoY. "Having invested in various strategic growth initiatives over the last year, we are encouraged by the results in the second quarter of 2025. Excluding the Orion license fee last year, the 5.8 per cent revenue growth was positively impacted by Nordic tender wins for our antibiotics portfolio. Furthermore, several products, including Imdur® from our Prescription Drugs (RX) segment, have shown strong performance this quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce approval of the medical device OraFID® as primary package for Flexilev®, our medical treatment for Parkinson disease, enabling personalized, fine-tuned treatment with minitablets," she added. Business area update and Q2 key figures During the second quarter, the Hospital (up 23.5 per cent YoY) business area delivered strong growth. Prescription Drugs and Consumer Health were down 2.8 and 3.5 per cent YoY respectively in the period. As part of the Prescription Drugs (RX) area, revenues of Imdur® delivered strong revenues in the period and is up 101.0% YoY. Flexilev®, the company's unique treatment for Parkinson's disease, delivered sales growth of 4.8 per cent YoY. Mysimba® revenues were lower than last year by 12% YTD, while variable between the quarters (-26.6% YoY). For the Hospital area, recent tender wins drove sales growth in the antibiotics portfolio, which is up 48.4 per cent YoY, whilst the Medical Nutrition portfolio showed 3.3.% growth. The company's third business area, Consumer Health, delivered mixed results (-3.5%). Revenues of Modifast were slightly down (-1.1%), whilst Eroxon® saw a 10.7 per cent increase in revenues. Operating results (EBIT) for the second quarter of 2025 amounted to NOK 6.3 million, compared to NOK 6.2 million in 2024, excluding milestone license fee. Operating costs ended at NOK 41.1 million, compared to NOK 39.4 million last year. Net financial items ended at negative NOK 8.1 million and profit before tax was negative NOK 1.5 million. Outlook Navamedic continues to see growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "The past six months have been marked by execution across multiple fronts, from product and company acquisitions to successful launches and impactful marketing initiatives. Several initiatives, such as the dne pharma acquisition, will take time to translate into our growth results but with a solid foundation and continued operational progress, we are well-positioned to realize our ambition of reaching NOK 1 billion in revenue," Andreassen concluded. Presentation Navamedic will present the results for the second quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision . The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionFinancial StatementDrug Approval

30 Apr 2025

·www.prnewswire.com

Navamedic Q1 2025: Strong start of the year and well-positioned for future growth

OSLO, Norway, April 30, 2025 /PRNewswire/ -- In the first quarter of 2025, Navamedic ASA (OSE: NAVA) , a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, reported revenues of NOK 132.0 million, representing a 9.2 per cent increase from the same period in 2024. EBITDA reached NOK 12.8 million, up from NOK 8.5 million last year. Gross margin improved to 40.7per cent, compared to 38.7per cent in Q1 2024. The strong performance was primarily driven by the Hospital area, particularly the antibiotics portfolio, supported by two long-term Nordic tenders secured in 2024. The company also experienced double-digit revenue growth in its Prescription Drugs (RX) area, contributing to the overall growth. "After investing in several strategic growth initiatives last year, we are pleased to see strong results already in the first quarter of 2025. The positive impact of the Nordic tender wins for our antibiotics portfolio has just begun to materialize. In addition, several products, including Mysimba® and Imdur® from our Prescription Drugs (RX) segment, delivered strong performance in the quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce the renewal of our agreement with TopRidge Pharma, securing the exclusive rights to market and sell Imdur® for another eight years. Over the past few years, we have systematically expanded and matured our product portfolio while investing in initiatives to drive future growth. The strong start to 2025 confirms the progress we are making," she added. Business area update and Q1 key figures During the first quarter, the Prescription Drugs (up 11.5 per cent YoY) and Hospital (up 15.2 per cent YoY) business areas delivered strong growth. Consumer Health had a steady development in the period (up 0.3 per cent YoY). As part of the Prescription Drugs area, revenues of Mysimba® increased by 7.3 per cent YoY. During the quarter, the European Medicines Agency's Human Medicines Committee also announced its review of Mysimba®. It affirmed that the benefits continue to outweigh the risks for weight management in adults with obesity or overweight. Imdur® and Nitrolingual® performed well in the quarter and were up 54 per cent and 22 per cent, respectively. Flexilev®, the company's unique treatment for Parkinson's Disease, delivered sales growth of 13 per cent YoY. Forlax® had a revenue decrease of 45 per cent due increased competition. For the Hospital area, the two tender wins drove sales growth in the antibiotics portfolio, which is up 32 per cent YoY, whilst the Medical Nutrition portfolio maintained steady sales. The company's third business area, Consumer Health, delivered stable results. Revenues of Modifast were steady during Q1, whilst Absolut Torr (up 49 per cent YoY) and ThermaCare (up 8 per cent YoY) experienced strong growth. Eroxon® saw a 9 per cent decrease in revenues, which is explained by a stock build-up in Q1 2024. Operating results (EBIT) for the first quarter of 2025 amounted to NOK 9.1 million, compared to NOK 4.9 million in 2024. Operating costs ended at NOK 40.9 million, compared to NOK 38.3 million last year. Net financial items ended at negative NOK 11 million and profit before tax was negative NOK 1.8 million. Outlook Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "We have had a strong start to 2025. We have several key hero products across our three business areas, many of which have the potential to succeed internationally. Part of our work moving forward will be to identify growth opportunities for these products to support future growth," Andreassen concluded. Presentation Navamedic will present the results for the first quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Financial Statement

29 Apr 2025

·www.pharmaindustrial-india.com

Navamedic Extends Imdur Distribution Agreement Until 2032

Navamedic ASA has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement. "It is a pleasure to announce that we have agreed with our great partner TopRidge Pharma, to revise and renew the distribution agreement for Imdur until 2032. Imdur is our second largest single brand and is currently marketed by us in the Nordics, the Netherlands, the Baltics, Greece and Cyprus. Although there is generic competition in this field, the original product is highly valued by the patients who often stay on the treatment for a long period of time," said Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic. Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched in Europe in 1985. Navamedic commenced distribution of the product as part of a strategic partnership and long-term distribution agreement with TopRidge Pharma Limited in 2016. "Imdur® remains an important product to Navamedic, and we appreciate the efforts made by TopRidge to update the Marketing Authorisations and to secure steady supplies to our markets. With the renewal of this agreement, we look forward to exploring further collaboration opportunities for additional products in the future," added Gamborg Andreassen.

Drug ApprovalLicense out/in

100 Deals associated with Isosorbide Mononitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00630	Isosorbide Mononitrate	C01DA14	DB01020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	China	Livzon Group Livzon Pharmaceutical Factory	01 Jan 1993
Angina Pectoris	United States	Promius Pharma LLC	30 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina, Stable	Phase 3	Brazil	Laboratórios Baldacci SA	01 Jul 2014
Myocardial Infarction	Phase 1	China	-	10 Oct 2013
Vasospasm	Phase 1	China	-	10 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate (Isosorbide Mononitrate XL (ISMN))	zpykdtguxb = dtdziydkkj thwenckhey (iapsduxwoa, kggqwbrcbw - evxnwxrroo) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	zpykdtguxb = njdipcawcz thwenckhey (iapsduxwoa, qhgzhkxnev - ikwjzfnnah) View more
NCT04310995 (ASRAB-pilot, ESC2024)	Phase 4	complication of coronary artery bypass graft	150	Nicorandil 15 mg daily	nseeficnsv(fhkqkipxtu) = fpkgheeqdh zctxycavym (ituzxzrxmh ) View more	Negative	30 Aug 2024
				Isosorbide mononitrate 50 mg daily	nseeficnsv(fhkqkipxtu) = dcshhxwtjn zctxycavym (ituzxzrxmh ) View more
NCT04051957 (CTgov)	Phase 2	Kidney Diseases \| Proteinuria \| Hypertension	9	Isosorbide Mononitrate (Isosorbide Mononitrate)	afiizqiaut = ozukbgdafa qiaiydjkwg (yvyqkdywkj, odbfkohqjr - mhrxwhwiow) View more	-	03 Aug 2022
				Placebo oral tablet (Placebo)	afiizqiaut = mfwiwjvxgv qiaiydjkwg (yvyqkdywkj, ojjsdvdems - fzqzfecypi) View more
NCT03171480 (NOPE, CTgov)	Phase 4	Obstetric Labor, Premature \| Pre-Eclampsia	176	Monoket Pill (Monoket Pill)	zlnxmxqzbe = xfkrvgjroc hsbalweypa (ohhragfodq, suaizrxskz - baurpydobg) View more	-	04 Jan 2022
				Placebo (Placebo Pill)	chflhlzdzb = qmqvgeaujt tppvhvahkd (jagmtepxvb, vgycuuwftq - bepjnuydrd) View more
NCT03171480 (Pubmed \| Am J Obstet Gynecol MFM)	Phase 4	Hypertension	176	Vaginal Isosorbide Mononitrate	fangahjpph(fysdjxnwct) = mmmlonnjuw dxlwyqmhnz (hfbypbfiku ) View more	Negative	27 Feb 2021
				Placebo	fangahjpph(fysdjxnwct) = sqguvqdsxe dxlwyqmhnz (hfbypbfiku ) View more
NCT02791906 (CTgov)	Phase 2	Chronic Kidney Diseases	8	ISMN (ISMN Only)	griajuxmcp(iszkbkbiey) = frrcvggghe bmfvyorowq (ynxhskthqc, 31.5) View more	-	13 Aug 2020
				Vitamin C+ISMN (ISMN AND Vitamin C)	griajuxmcp(iszkbkbiey) = nchandoxcx bmfvyorowq (ynxhskthqc, 1.26) View more
NCT02053493 (NEAT-HFpeF, CTgov)	Phase 2	Heart Failure	110	Placebo+Isosorbide Mononitrate (Isosorbide Mononitrate Crossover to Placebo)	mssxtbkill(foqmjhknxu) = epxosnhpig hoewsdxzvz (mcyscydyso, 4601) View more	-	28 Nov 2016
				Placebo+Isosorbide Mononitrate (Placebo Crossover to Isosorbide Mononitrate)	mssxtbkill(foqmjhknxu) = kmtxvsmxdf hoewsdxzvz (mcyscydyso, 6286) View more
NCT02053493 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 2	Heart Failure	110	Isosorbide Mononitrate	arwrhgskfr(aohpjjvlws) = gwwdfmsymg emakuvpotm (uxpodpnhxf, -780 to 17) View more	Negative	10 Dec 2015
				Placebo	-
NCT01430780 (Pubmed \| Coron Artery Dis)	Not Applicable	Coronary Artery Disease	60	ISMN 20 mg retarded release	kjhghqrtba(rasvmovwcq) = slkiokhpiu ilgidpeytq (ynwnxshbnw )	Negative	01 Nov 2013
				Placebo	kjhghqrtba(rasvmovwcq) = owduoiojqb ilgidpeytq (ynwnxshbnw )
NCT01130168 (0000-166, CTgov)	Phase 1	Hypertension	38	Isosorbide mononitrate extended release (ISMN ER) (ISMN ER)	xocytzakwh(zbmibdnazi) = ycwzypayiq tlpfvlbnrs (uqbncadakw, 4.5) View more	-	28 May 2012
				Amlodipine (Amlodipine)	xocytzakwh(zbmibdnazi) = lesotjycrz tlpfvlbnrs (uqbncadakw, 4.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis